Daily Newsletter

21 November 2023

Daily Newsletter

21 November 2023

WHO-led mission evacuates babies from Gaza’s Al-Shifa Hospital

Six ambulances provided and staffed by the Palestine Red Crescent have shifted the severely ill babies.

RanjithKumar Dharma November 20 2023

A second joint United Nations (UN) mission, led by the World Health Organization (WHO), in partnership with the Palestine Red Crescent Society, has evacuated 31 infants from Al-Shifa Hospital in northern Gaza to a southern Gaza hospital.

UNICEF, UNRWA and UN Mine Action are the other members of the mission.

Six ambulances provided and staffed by the Palestine Red Crescent transported the severely ill babies.

These babies were earlier shifted from the neonatal unit at Al-Shifa to a safer hospital area.

This move was initiated due to shortage of electricity needed for their life support and concerns about security risks within the hospital.

Health workers and patients jointly requested an evacuation as Al-Shifa Hospital could no longer operate due to shortages of clean water, fuel, medical supplies, food, and other essential items as well as the intense hostilities.

Senior WHO personnel, along with a medical specialist and a doctor, spearheaded the mission, accompanied by representatives from UNICEF, UNMAS, and UNRWA.

It involved medical staff from the Palestine Red Crescent Society, and their ambulance vehicles.

The operation included public health experts, logistics specialists, and security staff from UNDSS, OCHA, UNMAS/UNOPS, UNRWA and WHO .

According to WHO, two infants passed away before the evacuation occurred.

More than 250 patients and 20 health workers are still at Al-Shifa, urgently seeking evacuation.

Efforts are underway to plan and execute the evacuation for the remaining patients, their families, and the healthcare workers, stated WHO.

Is it time for the healthcare sector to fully embrace the benefits of digitalization and AI?

Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close